Table 3 Univariable and multivariable analysis of progression-free survival.

From: The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

 

Univariable

Multivariable

hazard ratio

95% CI

p

hazard ratio

95% CI

p

Age

  

0.116

   

 < 65

1

     

 ≥ 65

1.15

0.96–1.37

    

Sarcomatoid Feature

  

0.006

  

0.013

 No

1

  

1

  

 Yes

1.45

1.11–1.89

 

1.49

1.08–2.04

 

Nephrectomy

  

 < 0.001

  

0.142

 No

1.77

1.46–2.14

 

1.26

0.92–1.73

 

 Yes

1

  

1

  

Systemic Treatment

  

0.289

   

 Sunitinib

1

     

 Pazopanib

0.91

0.76–1.08

    

Anemia

  

 < 0.001

  

0.008

 No

1

  

1

  

 Yes

1.65

1.38–1.98

 

1.39

1.09–1.79

 

Hypercalcemia

  

0.001

  

0.565

 No

1

  

1

  

 Yes

1.79

1.25–2.57

 

1.15

0.70–1.91

 

LDH Elevation

  

0.010

  

0.848

 No

1

  

1

  

 Yes

1.44

1.09–1.91

 

1.04

0.64–1.70

 

ECOG Performance Score

  

 < 0.001

  

 < 0.001

 ECOG 0–1

1

  

1

  

 ECOG 2–3-4

2.24

1.84–2.74

 

1.82

1.37–2.41

 

Time to Systemic Treatment

  

 < 0.001

  

0.937

 < 1 year

1.51

1.26–1.82

 

1.01

0.75–1.34

 

 ≥ 1 year

1

  

1

  

Previous Cytokine Use

  

0.567

   

 No

1

     

 Yes

1.05

0.88–1.24

    

Bone or CNS Metastasis

  

 < 0.001

  

0.552

 No

1

  

1

  

 Yes

1.48

1.25–1.75

 

1.07

0.84–1.38

 

SII

  

 < 0.001

  

 < 0.001

 Low

1

  

1

  

 High

1.66

1.38–2.00

 

1.64

1.28–2.10

 
  1. CI confidence interval, CNS central nervous system, ECOG eastern cooperative oncology group, LDH lactate dehydrogenase, SII systemic immune-inflammation index.
  2. Significant values are in bold.
Back to article page